LIGAND PHARMACEUTICALS INC Q3 FY2026 earnings call

• Strategic Pivot & Scale: Ligand has transitioned to a pure royalty aggregation model, scaling its portfolio to over 200 commercial, clinical, and preclinical assets following the historic $730 million Zoma acquisition.
• Financial Efficiency: The company achieved a capital-light structure with core operating expenses reduced from $92 million in 2022 to an expected $50 million in 2026, despite adding Zoma’s operational footprint.
• Portfolio Growth Drivers: Significant growth is attributed to the launch of Filspare for FSGS, continued momentum in IGAN, and the integration of Zoma’s commercial assets (Ojemda, Vilspari, Maiplaifa).
• Deal Flow & Sourcing: The investment team expanded with new deal leads, reviewing over 180 opportunities in 2026 with a high conversion rate to CDAs (115 signed) while maintaining strict selectivity, closing only six major investments.
• Pipeline Catalysts: Management anticipates a catalyst-rich period through 2027, with up to seven pivotal readouts, including key data from Takeda programs (Mozogetamab, Osovampitor) and Palvella’s Cuturian Rapamycin.

Total core revenue was $78.7 million, a 9% decline year-over-year primarily due to the absence of $24.5 million in one-time SELZUVME outlicense income recorded in the prior year; excluding this item, core revenue grew 26%. Royalty revenue reached $70.3 million, representing a 51% year-over-year increase driven by the Zoma acquisition and strong performance from legacy assets. Filspare emerged as the largest royalty asset at $16.8 million (up 85% YoY), followed by Kypralis at $10.5 million and Ojemda/Otuver at $7 million each. Adjusted diluted EPS was $2.67, down from $3.09 in the prior year quarter, which included significant non-recurring income.

• EPS Guidance Raised: Adjusted diluted EPS guidance for full-year 2026 is increased to $9.50–$9.75 per share, up from the previous range of $9.00–$9.50.
• Revenue Guidance Maintained: Full-year 2026 royalty revenue guidance remains unchanged at $225–$250 million; total revenue is guided at $270–$310 million.
• Q4 Weighting: Revenue is expected to be heavily weighted toward Q4 due to a full quarter of Zoma royalties and tiered royalty rates stepping up later in the year.
• Long-Term Outlook: No update to the five-year framework provided at Investor Day 2025; a revised outlook will be presented on December 8, 2026, incorporating Zoma, Filspare approvals, and Palvella milestones.

• Clinical/Binary Risk: Portfolio development carries inherent binary risk; not all anticipated pivotal trials or FDA approvals (e.g., Palvella, Takeda programs) are guaranteed to succeed.
• Guidance Uncertainty: Timing of customer orders, regulatory milestone payments, and partner sales reporting creates uncertainty in top-line revenue, leading management to adopt a cautious approach in estimates.
• Regulatory/Reimbursement: Potential skepticism in US regulatory pathways for certain topical candidates could impact global prescriber confidence or reimbursement negotiations, though EU approvals may remain independent.
• Accounting Estimates: Royalty revenue for partners who have not yet reported sales is based on management estimates informed by sell-side consensus, which may require truing up in subsequent quarters.

Q: Analyst asks if deeper diligence on the Zoma portfolio reveals 'hidden gems' beyond initial valuation and if earnings contribution assumptions have changed. / A: CEO confirms that triage-based initial valuations missed some assets now showing positive news flow, uncovering option value in follow-on capital opportunities. He states there are no changes to the projected earnings contribution per share, noting that viability views for promising assets remain stable.

Q: Analyst asks about the long-term sales potential and royalty structure for Palvella's Cuturian Rapamycin given its recent PDUFA acceptance. / A: CEO highlights the PDUFA date in February as major news, estimating sales potential in the high hundreds of millions to $1 billion globally. He notes the royalty rate scales quickly from low double-digits up to nearly 10% (9.8%), making it a significant near-term growth driver.

Q: Analyst asks how the expanded portfolio affects the pace and volume of annual capital deployment needed to sustain growth. / A: CEO explains that the investment team has onboarded rapidly and is highly productive. While the pace of deployment may increase, the firm maintains strict selectivity. The strategy focuses on late-stage clinical deals under $100 million, leveraging existing capabilities to enhance option value without altering the core investment thesis.

Q: Analyst asks why Q4 royalty guidance appears conservative given strong Q3 results and what factors will shape the updated five-year outlook. / A: CFO acknowledges the lower end of implied Q4 royalties but expresses high confidence in reaching the mid-to-upper end. Conservatism stems from waiting for partner reports and uncertainty around order flows. The five-year outlook update on Dec 8 will incorporate Zoma, Filspare approval, and Palvella milestones.

Q: Analyst asks if the Zoma acquisition changes the technological complexity or clinical risk profile of future deals and why so many CDAs did not result in closed investments. / A: CEO states the strategy remains focused on late-stage, sub-$100M deals with high unmet need, unaffected by the acquisition. Paul Hadden adds that deal flow is upticking significantly (115 CDAs vs 69 last year) due to expanded team capacity, but the firm deliberately closes only ~5% of CDAs to maintain high standards.